IVD Antibody Development Services for NT-proBNP Marker

As a preeminent contract antibody development company, Creative Biolabs offers high-quality in vitro diagnostic (IVD) antibody development services targeting a wide range of biomarkers. Here, we focus on the NT-proBNP marker of heart failure (HF). We are committed to providing the highest quality of custom services and products at the most reasonable prices.

ProBNP is a 108-amino acid precursor peptide of the BNP (B-type natriuretic peptide) which is a 32-amino acid protein secreted from cardiac ventricles. On account of the enhanced wall tension in ventricles, ProBNP is catalyzed by a protease resulting in the inactive form of a 76 amino acids N-terminal-proBNP (NT-proBNP) and the biologically active form of BNP. Contrast to BNP, NT-proBNP owns a longer half-life and is not influenced by the management of exogenous BNP. It more relies on renal elimination and the half-life estimated is about 2 hours. NT-proBNP has been studied for diagnosis of HF and left ventricular systolic dysfunction (LVSD). It has been accepted by the HF classification of New York Heart Association that NT-proBNP levels were consistent with the clinical severity of the disease.

Figure 1. Schematic representation of proBNP processing and cross-reactivity of assays measuring BNP and NT-proBNP. ProBNP can be posttranslationally O-glycosylated (O-glyc) within the Golgi apparatus. Both O-glycosylated and non-O-glycosylated proBNP are cleaved to BNP and NT-proBNP in equimolar fashion by the enzyme furin and then secreted into the circulation. (Gruden, G. 2014)

NT-proBNP Marker of Heart Failure

HF usually can be mixed up with other situations, and it may co-exist with them. Markers are helpful in diagnosis, treatment monitoring and to inform prognosis. NT-proBNP is a superior marker for HF and it enables to be used together with other cardiac biomarker tests to measure heart stress and damage. It has been proven that increased NT-proBNP levels are invariably connected with raised mortality in patients with HF. There are several analytical advantages of NT-proBNP as a diagnostic marker of HF. Firstly, NT-proBNP is highly stable both in vivo and in vitro and NT-proBNP tests are matched to an ordinary standard and prove much less method variation than that of BNP approaches. Furthermore, the results seen with NT-proBNP will be about 8-10 times higher than those commonly seen, on account of their higher molecular weight and the strong in vivo stability.

Figure 2. Plasma Levels of proBNP, total BNP, and NT-proBNP in normal and heart failure. Bar graph showing the total BNP, proBNP (A) and NT-proBNP (B) levels in healthy subjects and heart failure patients with NYHA classes 1–2 and 3–4. (Nishikimi, T. 2013)

IVD Antibody Development Services for NT-proBNP Marker

IVD antibodies have been commonly used in immunodiagnostic kits for disease diagnosis and prognosis. Creative Biolabs has built a versatile IVD platform to provide custom biomarker-specific IVD antibody development services to global clients. In addition, Creative Biolabs provides one-stop diagnostic immunoassay development services, including feasibility analysis, assay design, assay protocol establishment, validation, and production. Along with over a decade of rich experience in providing excellent custom services for IVD antibody discovery, our services can totally meet your special requirements.

Please feel free to contact us for more information and a detailed quote.

Reference

1. Taylor, C. J. (2014). “The potential role of NT-proBNP in screening for and predicting prognosis in heart failure: a survival analysis”. BMJ open 4(4), e004675.
2. Nishikimi, T. (2013). “Direct immunochemiluminescent assay for proBNP and total BNP in human plasma proBNP and total BNP levels in normal and heart failure”. PloS one 8(1), e53233.
3. Gruden, G. (2014). “Natriuretic peptides, heart, and adipose tissue: new findings and future developments for diabetes research”. Diabetes Care 37(11), 2899-2908.

For Research Use Only.